With 14 approved programs in total, TRND has progressed two into clinical development.
For the past two years NIH has been trying to double its funds for developing orphan drugs. But the FY 2012 budget offered more of the same, as in the same $24 million of annual funding set aside for NIH’s Therapeutics for Rare and Neglected Diseases (TRND) program since its creation in 2009. The institute had sought $50 million for TRND this year and last.
Genetic Engineering & Biotechnology News, January 31, 2012 (Alex Philippidis)